← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Larix Bioscience, Llc
Sunnyvale, CA
$8,440,935
Total funding
26
Grants
Funding over time
peak $1.8M · FY2015–24$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,889,403 · 25
CDC$551,532 · 1
By mechanism
R43$6,951,541 · 25
R44$1,489,394 · 1
Investigators at Larix Bioscience, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Human glyco-engineered CHO cells$788,585
R44 · FY2018 · GM
Human glyco-engineered CHO cells$700,809
R44 · FY2017 · GM
Advancing a novel therapy for preeclampsia$385,000
R43 · FY2022 · HD
Improved carnosic acid congener compounds for Alzheimerâs disease$326,205
R43 · FY2022 · AG
Therapeutic antibody for hyperemesis gravidarum$300,847
R43 · FY2022 · HD
Silencing autoantibody secretion for SLE therapy$299,865
R43 · FY2023 · AI
Silencing autoantibody secretion for SLE therapy$299,773
R43 · FY2024 · AI
Overcoming pressure ulcers with engineered hormones and stem cells$295,923
R43 · FY2023 · AG
Therapy for ectopic calcification in pseudoxanthoma elasticum$285,766
R43 · FY2023 · AR
Pan-COVID Therapeutic$275,766
R43 · FY2022 · GH
PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical$275,766
R43 · FY2022 · GH
Therapeutic antibody for anorexia nervosa$259,606
R43 · FY2022 · MH
Therapeutic antibody for cancer-associated cachexia$252,282
R43 · FY2021 · CA
Targeted therapeutic for Netherton syndrome$252,000
R43 · FY2020 · AR
Novel therapy for myocardial ischemia-reperfusion injury$252,000
R43 · FY2021 · HL
Targeted Therapy for Type 1 diabetes$250,000
R43 · FY2020 · DK
Inhibiting GPR146 in hypercholesterolemia$249,734
R43 · FY2021 · HL
Novel therapies for obesity- or diabetes-related lymphatic dysfunction$245,728
R43 · FY2023 · HL
Dual Intracellular and Extracellular Expression Technology (dIEE) for Parkinsonâs Disease$225,000
R43 · FY2019 · NS
Novel GPCR-targeted therapy for preeclampsia$224,986
R43 · FY2018 · HD